Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2022

View Archived Issues

MAL protein seen to regulate epithelial-mesenchymal transition in gastric cancer

Pyruvate kinase isozyme M2 activators identified at the University of Michigan

Enanta Pharmaceuticals describes SARS-CoV-2 3C-like proteinase inhibitors

Novo Nordisk discovers GIP-R/GLP-1 receptor coagonists

Columbia University patents SERT/VMAT2 inhibitors

Angion Biomedica divulges new ROCK1/ROCK2 inhibitors

Trastuzumab engineered with bone-homing peptides for treating breast cancer metastasis to bone

Novel indole derivative shows potent antileukemia activity in zebrafish xenograft model

Pharmacological IRE1/XBP1s activation mitigates obesity-driven metabolic dysfunction

TRIM13 prevents pathogenic DNA-triggered inflammatory responses

Structure-function analysis of HER2-HER3 dimers in HER2-amplified cancers uncovers new target sites

Alvea's SARS-CoV-2 DNA vaccine Alveavax enters preclinical testing

BioVaxys reports ACE2 binding inhibition data with haptenized SARS-CoV-2 vaccine BVX-0320

Asep advances antibiofilm peptide technology for wound dressings

FDA grants orphan drug designation to HSB-1216 for uveal melanoma

Insilico Medicine nominates preclinical compound in QPCTL program

Intellia and ONK enter licensing and collaboration agreement for allogeneic NK cell therapies

BetterLife reports findings from preclinical neural plasticity study of BETR-001

CROI 2022: Predicting the future to get ahead of viruses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...